Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options across a range of therapeutic categories including eye care and infectious disease prevention. Their lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is FDA-approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05, an oral tablet for the prevention of Lyme disease. Learn more at TarsusRx.com.